NEW YORK (GenomeWeb) – Sygnis today announced it has signed a non-exclusive distribution agreement with Japanese firm Funakoshi.
Under the terms of the agreement, Sygnis has granted Funakoshi the rights to promote, market, and sell all existing and future products based on its TruePrime single-cell total genome amplification technologies in Japan.
Funakoshi is "an important gatekeeper in Japan, the second largest life science market in the world today," Sygnis CEO Pilar de la Huerta said in a statement. The firm sells research reagents as well as high-tech instruments for molecular biology, protein research, cell biology, and diagnostics to customers throughout Japan.
"We are very focused and committed to building up and expanding our distribution channel program in 2015 and only just have started with our extensive marketing activities in order to make our product widely available," de la Huerta added.
With offices in Heidelberg, Germany and Madrid, Spain, Sygnis specializes in the development and commercialization of products for DNA amplification and sequencing.